Unknown

Dataset Information

0

Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.

ABSTRACT: Emerging reports of SARS-CoV-2 breakthrough infections entail methodical genomic surveillance for determining the efficacy of vaccines. This study elaborates genomic analysis of isolates from breakthrough infections following vaccination with AZD1222/Covishield and BBV152/Covaxin. Variants of concern B.1.617.2 and B.1.1.7 responsible for cases surge in April-May 2021 in Delhi, were the predominant lineages among breakthrough infections.

SUBMITTER: Singh UB 

PROVIDER: S-EPMC8662202 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
| S-EPMC8117968 | biostudies-literature
Unknown Emerging vaccine-breakthrough SARS-CoV-2 variants.
| S-EPMC8437313 | biostudies-literature
Unknown Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State.
| S-EPMC8394820 | biostudies-literature
Unknown Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India.
| S-EPMC8143909 | biostudies-literature
Unknown Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
| S-EPMC8930394 | biostudies-literature
Unknown Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers.
| S-EPMC8778656 | biostudies-literature
Unknown Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.
| S-EPMC8569006 | biostudies-literature
Unknown Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico.
| S-EPMC8781434 | biostudies-literature
Unknown Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City.
| S-EPMC8439605 | biostudies-literature
Unknown Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
| S-EPMC8765759 | biostudies-literature